Nonsurgical bleeding (NSB) in heart failure (HF) patients with continuous-flow left ventricular assist device (CF-LVAD) support is the most common clinical complication. The aim of this study was to investigate the association between oxidative stress and platelet glycoproteins GPIbα and GPVI shedding on the incidence of NSB in CF-LVAD patients. Fifty-one HF patients undergoing CF-LVAD implantation and 11 healthy volunteers were recruited. Fourteen patients developed NSB (bleeder group) during 1 month follow-up duration, while others were considered nonbleeder group (n = 37). Several biomarkers of oxidative stress were quantified at baseline and weekly intervals in all patients. Surface expression and plasma elements of platelet receptor glycoproteins GPIbα and GPVI were measured. Oxidative stress biomarkers and platelet GPIbα and GPVI receptor-shedding (decreased surface expression and higher plasma levels) were found to be preexisting conditions in baseline samples of both groups of HF patients when compared with healthy volunteers. Significantly elevated oxidative stress biomarkers and platelet glycoprotein receptor shedding were observed in postimplant bleeder group temporarily when compared with nonbleeder group. Strong significant associations between biomarkers of oxidative stress and platelet glycoprotein receptor shedding were observed, suggesting a possible role of oxidative stress in platelet integrin shedding leading to NSB in CF-LVAD patients. Receiver operating characteristic analyses of GPIbα and GPVI indicated that the likelihood of NSB had a predictive power of bleeding complication in CF-LVAD patients. In conclusion, elevated oxidative stress may play a role in GPIbα and GPVI shedding in the event of NSB. Thus, oxidative stress and GPIbα and GPVI shedding may be used as potential biomarkers for bleeding risk stratification in those patients. ASAIO Journal 2018; 64:462-471.
Platelets are critical for the maintenance of the integrity of the vascular system and are the first line of defense against hemorrhage. 9 GPIbα and GPVI are two key platelet receptors that bind von Willebrand factor (vWF) and collagen, respectively, which initiate hemostasis at sites of vascular injury. 10 Metalloproteinase-mediated ectodomain shedding of platelet receptors has been recognized as a new mechanism for regulating platelet function. 11 Platelet dysfunction is an important cause of major bleeding after cardiac surgery. 12 Recent study reported that loss of the platelet surface receptors in HF patients, patients with mechanical circulatory support device, and patients with extracorporeal membrane oxygenator support may contribute to ablated platelet adhesion/activation and limit thrombus formation under high/pathologic shear conditions. 13 Studies also revealed that nonphysiological high shear stress may also contribute to the shedding of different important platelet receptor glycoproteins. [14] [15] [16] Several biochemical pathways that induce shedding of GPIbα or GPVI have been identified. [17] [18] [19] [20] [21] While these pathways might be dependent or independent of platelet activation, the loss of these functional receptors may result in defective platelets. Defects affecting normal surface expression and shedding of GPIbα or GPVI may result in mild or more severe bleeding complication. 13 Oxidative stress, defined as an excess production of reactive oxygen species (ROS) relative to antioxidant defense, has been Moreover, increased oxidative stress is found to relate with the functional severity of HF, with the highest levels being noticed in patients in functional class III and IV. 23 Our recent reports demonstrated that increased levels of oxidative stress biomarkers and mechanistic insight of platelet apoptosis are linked to bleeding complication in some HF patients with CF-LVAD support. 24, 25 Oxidative stress may also influence the alteration of platelet and leukocyte functionality in CF-LAVD patients with systemic inflammation, infection, and sepsis. 26 A previous study showed that higher levels of oxidative stress have a potential role in mediating abnormal bleeding and was associated with increased serum malondialdehyde and decreased superoxide dismutase (SOD) levels. 27, 28 The regulation of platelet function is finely tuned by a balance between the vasculature's redox environment and the oxidative processes that occur in it. 29 Prior study on murine and human model suggested that oxidative injury of platelets may attenuate their function by shedding key adhesion receptors on platelet surface. 30 Thus, the importance of redox regulation of important platelet surface glycoprotein functionality cannot be underestimated. Unfavorable response to CF-LVAD implantation, leading to increased production of oxidative stress, in combination with nonphysiological mechanical factors, could induce platelet glycoprotein shedding. The role of platelet surface receptor glycoproteins and oxidative stress response of NSB associated with CF-LVADs has been elusive. The current study focused on the status of oxidative stress and their associations with platelet glycoproteins GPIbα and GPVI shedding during NSB in CF-LVAD patients.
Methods

Study Population
Fifty-one HF patients undergoing CF-LVAD implantation and 11 healthy volunteers were recruited in our study. The CF-LVAD therapies were for either as bridge to transplant or as destination therapy. Among the different CF-LVADs implanted, 21 patients received the HeartMate II (Thoratec Corp, Pleasanton, CA), 11 received the Jarvik 2000 (Jarvik Heart, New York, NY), and 19 had HeartWare HVAD (HeartWare Inc, Framingham, MA).
Patient Selection Criteria and Ethical Aspects
Patients aged between 18 and 70 years undergoing CF-LVAD implantation were enrolled in our study. All the subjects were enrolled after signing informed consent form in accordance with the Declaration of Helsinki. Patients with history of malignancy and preexisting inflammatory conditions were excluded from our study. Healthy volunteers without any history of any cardiovascular disease were included as reference. Blood samples and background information were collected from each patient according to our institutional Review Board protocol.
Sample Collection and Processing
Baseline (preoperative: Pre-OP) and postoperative (at 1, 2, and 3 weeks and 1 month: POD-1W, 2W, 3W, and 1M) blood samples from the HF patients were collected in ethylenediaminetetraacetic acid (EDTA)/ citrate-anticoagulated vacutainer tubes. Reference blood samples from healthy volunteers were collected once. Samples were aliquoted, processed, and used for further analysis according to the study protocol.
Assessment of Oxidative Stress
To investigate the extent of oxidative stress, we measured several biomarkers of oxidative stress in platelets, leukocytes, erythrocytes, and even in plasma samples of the study population according to previously published procedures. 25, [31] [32] [33] In brief, generation of ROS in platelets, neutrophils, lymphocytes, and monocytes were quantified by our standard laboratory procedures published earlier, and the results were expressed as mean fluorescence intensity in arbitrary unit for each cell types. 33 As the status of oxidative stress cannot be confirmed by measuring only ROS, it is important to look into the antioxidant status also, as the oxidative stress best explained by the balance between ROS and antioxidant enzyme. To evaluate the antioxidant status, we further quantified potent antioxidant enzyme SOD (kit: Cell Technology Inc. Mountain View, CA) in erythrocytes and total antioxidant capacity (TAC, kit: Randox Laboratories, Antrim, UK) in plasma samples by using commercially available kits according to the manufacturer's instructions. The data for SOD and TAC were expressed as units per milliliters (unit/mL) and millimole per liters (mmol/L), respectively. We further estimated the concentration of oxidized low-density lipoprotein (oxLDL) in plasma by ELISA using a commercially available kit (Mercodia Inc, Winston Salem, NC) following the manufacturer's instruction to explore overall status of oxidative stress. Details of each experimental procedure were found in our previously published literatures. 24, 25, 32, 33 
Assessment of Platelet Surface Receptors GPIbα and GPVI Shedding
To evaluate the shedding of 2 important platelet surface glycoprotein receptors GPIbα and GPVI, we looked in the surface expression and plasma elements of both receptors in all of our study samples. Reduction in the surface expression and elevation in the plasma levels indicated the shedding of those receptors. Flow cytometry and ELISA were used to estimate surface expression and plasma elements of these receptors according to the following procedures.
Assessment of Platelet Surface Receptors GPIbα and GPVI by Flow Cytometry
Evaluation of surface expression of platelet membrane glycoproteins GPIbα (CD42b, clone HIP1; BioLegend, San Diego, CA) and GPVI (eBioscience, San Diego, CA) was performed with the use of specific antibodies and multicolor whole-blood flow cytometry, as described in our previous study. 14 In brief, 5 μl aliquot of EDTA-anticoagulated whole blood samples with 25 μl of 10 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer were incubated with 10 μl each of fluorescein isothiocyanate (FITC for CD42b)-and eFluor 660 (eFlu for GPVI)-conjugated monoclonal antibodies raised against human cells and isotype-matched negative controls subjects (FITC and eFlu for mouse IgG1, κ). In each sample, another 10 μl phycoerythrin-conjugated anti-human CD41 antibody was added to identify platelet population. All the samples were incubated for 30 minutes in the dark at room temperature. Thereafter, the cells were fixed with 1% paraformaldehyde, kept in dark for 30 minutes at 4°C, and analyzed in a flow cytometer.
Assessment of Plasma Levels of GPIbα and GPVI by ELISA
To determine the plasma levels of GPIbα (cat no: MBS701708) and GPVI (cat no: MBS915183), we used commercially available ELISA kits from MyBioSource Inc., San Diego, CA. These assays employ the quantitative sandwich enzyme immunoassay technique. Antibody specific for either GPIbα or GPVI has been precoated onto microplate. Standard or plasma (100 μl for both) was added to each well, and they were incubated at 37°C for 2 h. The liquid of each well was removed, with 100 μl of biotin antibody added to each well, and the resultant samples were incubated at 37°C for 1 h. After washing three times, the plate was inverted and blotted against clean paper towels. horseradish peroxidase (HRP)-avidin (100 μl) was added to each well, and the sample was incubated at 37°C for 1 h. Washing lasted for five times. TMB substrate (90 μl) was added to each well, and the sample was incubated for 15-30 minutes at 37°C away from light. Stop solution (50 μL) was added, and the plate was gently tapped to ensure thorough mixing. The absorbance was determined within 15 minutes on a microplate reader set to 450 nm. The detection ranges of the kits were 0.156-10 μg/ml for GPIbα and 46.88-3000 pg/ml for GPVI.
Statistical Analyses
All analyses were performed with GraphPad Prism, version 6.07 (GraphPad Software, Inc., La Jolla, CA) and SAS software, version 9.4 (SAS Institute, Cary, NC). The data are presented as mean ± SD (standard deviation) or median with interquartile range. Statistical differences were determined by using χ 2 test, Student's t-test, Mann-Whitney U test, and one-way ANOVA (Wilcoxon rank-sum test or Kruskal-Wallis test), as applicable. Univariate analysis was carried out using Spearman's rank correlation test to find out the relation between two measurable parameters as continuous variables, and the result was expressed as rho value. Statistical significance was assigned at p < 0.05. For spearman's rank correlation analysis to identify any correlation between different biomarkers of oxidative stress and platelet receptor shedding, paired oxidative stress data for each biomarker from baseline to postoperative day 30 in each patients plotted against the matched platelet receptor shedding data. Multivariate logistic regression models were created to evaluate impact of relevant baseline factors and change in levels of biomarkers (from baseline) on incidence of postoperative bleeding. There were two multivariate logistic regression models created; one each using GPIbα and GPVI. The covariates in GPIb model included BMI and a variable derived from the equation of GPIbα change from baseline (described in the results). Similarly, GPVI model included BMI and variable derived from the equation of GPVI change from baseline (described in the results). BSA was not included as a covariate as BMI and BSA use same factors in their calculations. Apart from biomarkers, the covariates were selected based on purposeful selection of variables, i.e., any variables significantly different on univariate analysis. Any measured parameter was treated as a variable, either continuous (when computing univariately for correlation) or dichotomous (when examining association). We did not include variables known to interact (GPIbα and GPVI) in the same model to avoid interaction-related bias. The receiver operating characteristic (ROC) curves were generated for both models.
Results
NSB and Demography
Among 51 HF patients, 14 experienced at least one episode of NSB within 1 month after CF-LVAD support (bleeder group). Nonsurgical bleeding was defined according to interagency registry for mechanically assisted circulatory support (INTER-MACS) classification. CF-LVAD patients having bleeding that requires a transfusion of 4 or more units of packed red blood cells or causes hemodynamic instability requiring inotropic infusion or surgical reintervention was considered bleeders. Comparative analyses of demographic and clinical characteristics of the patients in the bleeder group and those who did not experience NSB (nonbleeder group) before CF-LVAD implantation are summarized in Table 1 . All the patients were transfused with either red blood cells (RBCs) or fresh frozen plasma or platelets. Anticoagulation regimen at the time of bleeding was clinically optimized individually for each patient.
Clinical Hematology
There were no significant differences in most of the common hematology and blood chemistry data (white blood cell, RBC, hematocrit (HCT), blood urea nitrogen, creatinine, international normalized ratio (INR), and partial thromboplastin time) between the nonbleeder and bleeder groups before and after CF-LVAD implantation throughout the study period as observed from our hospital database. At the baseline (Pre-OP), there was no significant difference in hemoglobin counts between nonbleeder and bleeders (11.8 ± 1.9 vs 11.4 ± 1.6; p > 0.05). Hemoglobin content was reduced temporally in both the nonbleeder and bleeder groups with similar trends. After 1 month of CF-LVAD implantation, the hemoglobin counts were significantly reduced by 20% (11.8 vs 9.4; p < 0.05) and 25% (11.4 vs 8.5; p < 0.05) in nonbleeder and bleeder groups, respectively, when compared with their corresponding baseline values. We did not notice significant difference in the platelet count between the bleeder and the nonbleeder groups at baseline (178.7 ± 46.7 vs 197.1 ± 85.4 × 10 with the healthy volunteers (Figure 1) . Moreover, ROS generation from platelets was significantly 26% elevated in the bleeder group compared with the nonbleeder group before CF-LVAD implantation. After CF-LVAD implantation, we noticed temporal changes in ROS generation from all cell types in both groups. Intraplatelet ROS generation was found to be temporarily increased up to the end of the study duration, whereas the levels of intraplatelet ROS decreased in the nonbleeder group. We noticed significant elevation of intraplatelet ROS in bleeder group compared with nonbleeder at postimplant day 14, 21, and 30. The trends of ROS generation in neutrophils and lymphocytes were similar in both nonbleeder and bleeder groups. In all cases, ROS generation was found to be significantly higher in bleeder group compared with nonbleeder group at postimplant day 30 (POD-1M).
Change in SOD, TAC, and oxLDL
Significantly lower levels of antioxidant enzyme SOD in erythrocytes and TAC in plasma were detected among both the nonbleeding and bleeding groups of HF patients at baseline compared with the healthy volunteers (Figure 2A and  2C) . The baseline levels of SOD and TAC between the nonbleeder and bleeder groups were comparable to each other. After CF-LVAD implantation, temporal decrease in SOD and TAC levels was significantly prominent in bleeder group in comparison to nonbleeder group. The lowest levels of SOD and TAC were observed in the bleeder group at the end of the study (Figure 2B and 2D) . A higher level of plasma oxLDL, another important biomarker of oxidative stress, was also observed in both groups of HF patients compared with the healthy volunteers, which was also higher preimplant and postimplant in the bleeder group and continued to increase temporally postimplant (Figure 2E and 2F) . Figure 3 demonstrates data from flow cytometric and ELISA analysis to investigate surface expression and plasma levels of platelet GPIbα and GPVI receptors among healthy volunteers and HF patients before and after multiple time points of CF-LVAD implantation. At baseline, the surface expression of GPIbα and GPVI receptors were significantly lowered in the bleeder group when compared with the nonbleeder group and healthy volunteers, indicating preexisting condition of decreased receptors in bleeder group before CF-LVAD implantation ( Figure 3A and 3E) . While looking at postimplant surface expression, we noticed a progressive decrease in GPIbα and GPVI receptors in bleeder groups and became lowest at 1 month after CF-LVAD support (Figure 3B and 3F) . In case of nonbleeder group, the temporal changes were not so prominent. The temporal change in GPIbα and GPVI receptors on platelet surface remained always significantly lowered in bleeder group in comparison to nonbleeder group. Contrary to reduced surface expression of platelet GPIbα and GPVI receptors, we noticed significantly elevated plasma levels of those two receptors among bleeder group compared with the nonbleeder and healthy volunteers at baseline (Figure 3C  and 3G) . Moreover, postimplant temporal changes in elevated plasma levels of GPIbα and GPVI were found to be significantly higher at all time points in bleeder group compared with the nonbleeder group (Figure 3D and 3H) . All indicating proteolytic shedding of GPIbα and GPVI receptors in circulating plasma, especially in bleeder group.
Change in Shedding of Platelet Receptors Glycoproteins: GPIbα and GPVI
Likelihood of Bleeding Prediction by GPIbα and GPVI Receptor Shedding
After assessing the GPIbα and GPVI shedding as a potential marker of the bleeding at different post-LVAD time points, we evaluated the marker by change in their value at these time points from baseline value. We hypothesized that scale of increase in the GPIbα and the GPVI shedding from the baseline level, as well as the frequency of increase from baseline, is proportional to the likelihood of bleeding. First, we calculated the difference of concentration from baseline at each available follow-up time points up to 1 month study period. Then we calculated the mean of the difference in those follow-up time point concentrations. We also assessed the frequency of increase in the concentrations from baseline. We then used following equation to calculate likelihood of bleeding for the GPIbα and the GPVI shedding.
Likelihood of NSB
where A is the mean difference in concentration from baseline; B is the frequency of increased concentrations from baseline; C is the total frequency of follow-up concentrations
Multivariate Regression and ROC Analysis for Likelihood of Bleeding Prediction Model
In a multivariate logistic regression model, we applied the likelihood bleeding data points to evaluate its relation to the bleeding. The ROC curve for the GPIbα and the GPVI likelihood of bleeding unit is shown in Figure 4 . The estimated area under the curve (AUCs) were 0.9514 (95% confidence interval [CI], 1.203-5.649; p = 0.0152) for GPIbα and 0.9236 (95% CI, 1.001-1.007; p = 0.0114) for GPVI. According to these statistics, if we randomly select a patient with NSB and a patient without NSB, the probability of bleeding (while controlling BMI) being greater for the bleeding patient than the nonbleeding patient are 0.9514 (GPIbα) and 0.9236 (GPVI). To test whether the AUCs of GPIbα and GPVI were significantly different from 0.5, wald 2 statistic of 5.89 and 6.40 were obtained (using the estimated standard errors of 0.395 and 0.001), which yield p values of 0.015 and 0.011, respectively, significant at a Type I error rate of 5%. Thus, the discriminating power of the biomarker of the predicted probability for bleeding by the GPIbα and the GPVI likelihood of bleeding units are significantly greater than that of chance alone. Thus, the measured GPIbα and GPVI shedding as a potential biomarker have a predictive power for NSB.
Correlation Between Biomarkers of Oxidative Stress and Platelet Receptor Shedding
To investigate relationship between biomarkers of oxidative stress and shedding of platelet GPIbα and GPVI receptors, we conducted Spearman's rank correlation test in all CF-LVAD patients ( Table 2) . Our data clearly indicated that surface expression of GPIbα and GPVI receptors correlated negatively with generation of ROS and levels of oxLDL and correlated positively with concentration of SOD and TAC. As expected, opposite strong correlations were evident in case of plasma elements of GPIbα and GPVI receptors and oxidative stress markers. Thus, the shedding of these 2 important platelet receptors correlated with the elevation of oxidative stress among HF patients with CF-LVAD support. In multivariate regression analysis, oxidative stress biomarkers were significantly associated with platelet receptor glycoproteins shedding after controlling possible covariates (p < 0.01). LVAD) implantation (B, D, F, H ). *p < 0.05 is considered significant.
Discussion
The major bleeding complication in CF-LVAD patients may result in significant morbidity, and its incidence has been estimated to range between 18% and 40%. 3, [34] [35] [36] The etiology of bleeding diathesis can be multifactorial in CF-LVAD patients. The development of acquired von Willebrand syndrome (AvWS) is one of the most discussed factor in which patients experienced with mechanical destruction and proteolysis of high-molecular weight multimers of vWF, induced by CF-LVADs-generated nonphysiological high shear stress. [37] [38] [39] [40] Although the CF-LVAD patients with AvWS may result in reduced vWF-associated platelet activity and aggregation, not all of them experience major bleeding. [40] [41] [42] The key function of platelets is to prevent bleeding; subsequently, it stands to reason that abnormal platelet function may be a contributing factor to NSB events. 25 We recently reported that mechanistic insight of platelet apoptosis is linked to elevated oxidative stress in CF LVAD patients and were associated with bleeding complications, and there is an important role of oxidative stress and platelet mitochondrial damage because of inflammation/ infection during CF-LVAD support. [24] [25] [26] In our current study, we hypothesized that persistent oxidative stress and reduced surface expression or shedding of two important platelet receptor glycoproteins GPIbα and GPVI may give rise to NSB complication among CF-LVAD patients.
Platelets are unique in their structural assembly, though they are anucleate but have distinct mitochondria and play major role in hemostasis and thrombosis. 43 Plasma membrane of platelets is composed of phospholipid bilayer and is the site of expression of various surface receptors, including GPIbα, GPVI, and lipid rafts, which helps in signaling and intracellular trafficking related to cellular homeostasis. 43 Platelets are well known as key mediators of hemostasis, and their activity and fate have been reported to be controlled by oxidative stress during cell activation. [44] [45] [46] [47] [48] These conditions can dramatically affect platelet physiology. Other study demonstrated that redox control of cellular homeostasis is a key determinant of platelet destiny. 49 However, the precise mechanisms involved in redox modification of platelet surface receptor dysfunction are not clear. It is noted that the clinical role of oxidative stress in platelet function and thrombosis/bleeding is unclear and complex so far. Nonetheless, redox regulation of the platelet is crucial to the modulation of its function. Prior studies showed that redox sites on the surface of the platelet most likely impacts platelet function, as it does in other biological processes. These include integrin-mediated adhesion, virus entry into the cell, and importantly receptor shedding. 50 In our study, we noticed significantly higher ROS generation not only from platelets but also from neutrophils, lymphocytes, and monocytes in the CF-LVAD patients who developed NSB when compared with patients without bleeding complication. We also noticed concomitant decrease in SOD, TAC, and elevated oxLDL, suggesting that the total antioxidant capacity might not be strong enough to minimize the deleterious effect of ROS during NSB. These observations explain the severity of oxidative stress in CF-LVAD patients, especially in bleeder group. The increased formation and release of ROS, as well as the modified content of endogenous or exogenous antioxidants, may play a role not only in platelet destiny and thrombus formation, but also in the development of other diseases, including bleeding complications.
The balance between hemostasis and thrombosis relies on a finely tuned adhesive response of blood platelets. Inadequate adhesion leads to bleeding, whereas excessive or inappropriate adhesion leads to thrombosis. 51 We noticed temporarily reduced surface expression and elevated plasma levels of two important platelet glycoproteins (GPIbα and GPVI) in bleeder group when compared with nonbleeder group, indicating possibilities of proteolytic shedding during the CF-LVAD support. Thus, the proteolytic shedding of those glycoprotein receptors from platelet surface may produce abnormal platelets, which may facilitate the process of NSB event in CF-LVAD patients. In univariate analysis, strong correlations between the biomarkers of oxidative stress and platelet glycoprotein receptors shedding in the HF patients were observed in our study. In multivariate regression analysis, oxidative stress was significantly associated with platelet glycoprotein receptors shedding after controlling for BMI. Thus, our study may suggest that oxidative stress may partially play a role in accelerating receptor shedding, leading to platelet dysfunction in CF-LVAD patients and subsequent NSB. We further verified the predictability of the likelihood of NSB using the platelet shedding values and performed ROC analysis. Based on this statistical analysis, the likelihood of NSB would be a good biomarker as a diagnostic test for bleeding complication in CF-LVAD patients. Thus, the implications, therefore, are that the regulation of platelets by oxidative stress is an important biomedical issue. A thorough understanding of these mechanisms and how they interact with other platelet signaling events is of the utmost importance for the development of novel therapeutic targets so that we can protect against inappropriate thrombus formation or bleeding complications in CF-LVAD patients. Platelet glycoprotein shedding could be because of other factors such as long-term exposure to the high shear stress flow environment, as well as the artificial blood contacting materials found in CFLVADs. Recently, it was shown that the nonphysiological high shear stress (NPHSS) environment that occurs with CF-LVADs may be responsible for platelet dysfunction as evidenced by GPIbα, GPVI, and GPIIbIIIa receptor shedding. [14] [15] [16] Understanding the role of oxidative stress and NPHSS from CF-LVAD as contributory factor in platelet glycoprotein shedding may enable development of effective medical management strategy.
Study Limitations
We acknowledge that there are some limitations in this prospective observational study. The sample size was relatively small. Not all CF-LVAD patients were enrolled for this study.
Medication might have some impact on oxidative stress status. Recent changes in medications should be addressed in further studies to rule out drug-drug interactions or a new side effect. A larger cohort of CF-LVAD patients with bleeding complication is needed to confirm our initial findings.
Conclusions
Elevated oxidative stress may play a role in GPIbα and GPVI shedding in the event of NSB. Thus, oxidative stress and GPIbα and GPVI shedding may be used as potential biomarkers for bleeding risk stratification in those patients. 
